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ABSTRACT
Background: Immune checkpoint inhibitors, targeting the molecules CTLA-4, PD-1 
and PD-L1, showed efficacy against several type of cancers and are currently used in 
clinical practice. An important biological variable that influences innate and adaptive 
immunity is the sex, acting through genetic, hormonal and environmental factors. The 
overall differences between sexes could be crucial to evaluate the response to ICIs.
Materials and methods: We performed a meta-analysis of Phase II-III Clinical 
Trials published up to June 2017 in which anti-CTLA-4, anti-PD-1 and anti-PD-L1 
were studied. We extracted the OS and PFS HR differentiated by sex from subgroups 
analysis of each trial. We analyzed the three classes of drugs separately.
Results: We selected 36 Phase II-III Clinical Trials, 9 of which reported results 
for OS and 6 for PFS. We analyzed 2 Clinical Trials for OS with anti-CTLA-4, including 
1178 patients, observing a benefit for males vs females (HR 0.65, 95% CI 0.55-0.77 
vs HR 0.79, 95% CI 0.65-0.96, p 0.078).
Not statistically significant results were observed with anti-PD-1 neither for 
OS (males vs females: HR 0.72, 95% CI 0.64-0.83 vs HR 0.81, 95% CI 0.70-0.94, p 
0.285) neither for PFS (males vs females: HR 0.66, 95% CI 0.52-0.82 vs HR 0.85, 
95% CI 0.66-1.09, p 0.158). We cannot perform a meta-analysis for anti-PD-L1 due 
to the lack of data.
Conclusions: Different mechanisms could be involved in sex differences 
with regard to immunotherapy. These differences could be relevant to identify 
immunological targets in order to draw studies exploring novel combinations of 
immunotherapy agents.
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INTRODUCTION
Several immune checkpoint inhibitors (ICIs), mostly 
against the molecules CTLA4, PD-1 and PD-L1, are 
approved in clinical practice, given the promising results in 
several types of solid tumors. [1] Interestingly, the target of 
these drugs is not the tumor, as conventional chemotherapy 
and targeted therapies, but critical checkpoints of the 
patient’s immune system. In fact CTLA-4 is predominantly 
expressed on CD4+ “helper” T lymphocytes and its 
physiological engagement by CD80 and CD86 molecules 
down-regulates the T cell response. [2] PD-1 is mainly 
expressed by activated T cells and binds PD-L1, expressed 
on the surface of antigen presenting cells (APCs) and 
tumour cells, inducing a negative control damping of the 
immune response. [2]. These drugs are able to unleash 
existing T cell, permitting the expansion of effector 
cytotoxic T cells, that could recognize and destroy the 
tumor.
Currently, despite the remarkable success also in 
the metastatic setting of several approved monoclonal 
antibodies, such as anti-CTLA4 (Ipilimumab, 
Tremelimumab) and anti-PD1/PD-L1 (Nivolumab, 
Pembrolizumab, Atezolizumab, Avelumab, Durvalumab), 
a good percentage of patients do not respond to treatment 
and may develop different pattern of toxicities, known as 
immune related adverse events (irAE).
Various biomarkers (e.g. PD-L1 expression, 
intratumoral immune infiltrate, mutational burden etc...) 
have been supposed to reflect the ICIs pharmacodynamics 
and to predict ICIs efficacy and/or toxicity, but their 
relevance is still unclear. [3].
It was shown that the sex, defined by the differential 
organization of chromosomes, reproductive organs, and 
sex steroid levels, represents an important biological 
variable that influences innate and adaptive immunity. The 
sex influence on the immune system is well documented in 
the pathogenesis and prognosis of autoimmune diseases, 
infections and malignancies [4].
Generally, as showed in various immune-modulated 
disease, adult females make a stronger innate and adaptive 
immune responses than males. In particular, females have 
a higher incidence of autoimmune diseases than males and 
the onset and the severity is related with the reproductive 
status, suggesting that their pathogenesis could be 
influenced by sex hormones. [5, 6].
The different innate immune responses among 
mammals suggests that some sex differences may be 
germline encoded. Indeed, in preclinical models of human 
cells or rats tissue, females show higher expression than 
males of genes along TLR pathways, like Toll-like receptor 
7 (TLR7) gene, encoded on the X chromosome, as well as 
a better induction of type I interferon (IFN) responses. [4, 
7-10] Murine models were recently studied to evaluate the 
different sexual response to ICIs. The treatment with anti-
PD-L1 Abs appeared to be more efficacious in female than 
in male murine model of melanoma. [11]. Interestingly, a 
recent research reports that PD-1 expression and function 
correlate with a better response to hormone treatment. [12] 
Despite of great interest in the improved clinical outcomes 
Figure 1: Consort diagram for trial selection.
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of cancer patients with immunological approach, only 
few data are published regarding potential sex-based 
differences in responses and toxicity to immunotherapy.
In this context, the overall differences between 
males and females could be crucial to evaluate the 
response to ICIs and the toxicity profile.
On these bases, we performed a phase II and III 
trials’ meta-analysis to determine sex-differential effects 
of ICIs in cancer patients.
RESULTS
We selected 36 Phase II and Phase III Clinical 
Trials published up to June 2017 in which immunotherapy 
was tested (anti-CTLA-4, anti-PD-1 and anti-PD-L1) 
in patients affected by solid cancers. Of these studies, 
17 were Phase III Trials subdivided as following: 8 on 
melanoma, 6 on NSCLC, 1 on RCC, 1 on head and neck 
tumors and 1 on urothelial carcinoma. [13-30] Nineteen 
were Phase II Trials: 10 on melanoma, 5 on NSCLC, 1 
on RCC and 3 on urothelial cancer. [31-50] From this 
selection, 2 studies were excluded because results were 
published only as abstracts, 21 because the subgroup 
analysis differentiated by sex was not reported and 2 
because the patients in the control arm received ICIs. 
(Figure 1).
In the final statistical analysis for OS 9 studies 
were selected as reported in Table 1, including the 
three classes of drugs. [13, 16, 20, 25-30] The patients 
enrolled in the standard arm received a platinum doublet 
chemotherapy in first line or Docetaxel in second line for 
NSCLC, Everolimus for RCC, Dacarbazine or Gp100 for 
melanoma, investigator’s choice chemotherapy (Paclitaxel, 
Docetaxel or Vinflunine) for urothelial cancers. The 
patients were treated in first or second line, according to 
the protocol. Only two trials, CheckMate-025 on RCC and 
Keynote-045 or urothelial carcinoma, enrolled patients in 
third line of treatment. [29, 30].
We conducted a meta-analysis dividing the selected 
trials according to the target of the studied drug. We 
cannot perform a meta-analysis for anti-PD-L1, because 
only one study was available, showing a HR in females of 
0.64 (95% CI 0.49-0.84) vs HR 0.79 (95% CI 0.64-0.97) 
in males. [25].
Figure 2: Forest Plot for OS with anti-CTLA-4.
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We performed a meta-analysis for OS with anti-
CTLA-4 including 2 studies enrolling patients with 
melanoma treated with ipilimumab. (Figure 2) These 
trials enrolled 1,178 patients, 702 males (59.6%) and 
476 females (40.4%). Overall, 480 males and 310 
females received experimental treatment. [13, 16] The 
heterogeneity test between the two groups showed a 
benefit for males vs females (HR 0.65, 95% CI 0.55-0.77 
vs HR 0.79, 95% CI 0.65-0.96, p 0.078).
We considered 6 Clinical Trials with anti-PD-1 
for OS. Overall we analyzed 3,792 patients, 2,514 males 
(66.3%) and 1,278 females (33.7%), 55.1% (1386) 
and 53.4% (683) of which received immunotherapy, 
respectively. [22, 26-30] In this analysis we observed a not 
statistically significant lower HR for males than females 
(HR 0.72, 95% CI 0.64-0.83 vs HR 0.81, 95% CI 0.70-
0.94, p 0.285), as reported in Figure 3.
Finally, we performed a meta-analysis for PFS, 
considering one Phase II and 5 Phase III Trials, as 
reported in Table 2. All the 6 studies randomized patients 
to receive anti-PD-1 (Pembrolizumab in 3 studies or 
Nivolumab in 3 studies). [22, 26-29, 32] The patients 
in the control arms received chemotherapy in first 
or second line, according to the trial. Only one study 
enrolled patients after failure of two lines of treatment. 
[32] Overall, we analyzed 3,274 patients, 2,007 males 
(61.3%) and 1,267 females (38.7%), 1,176 and 728 of 
which received experimental treatment, respectively. The 
heterogeneity test between sexes was not statistically 
significant, despite the HR lower in males group (HR 
0.66, 95% CI 0.52-0.82 vs HR 0.85, 95% CI 0.66-1.09, p 
0.158).(Figure 4) No PFS data differentiated by sex were 
available for anti-CTLA-4 or anti-PD-L1.
DISCUSSION
Males and females differ in the immune response 
to infections and vaccines and in the predisposition to 
develop autoimmune diseases. [4].
The observation that not only hormonal factors but 
also genetic, and environmental mediators are involved in 
sex-based immunological differences lead to hypothesize 
that different outcome during immunotherapy could 
depend on the patient’s sex.
Table 1: Clinical trials selected for OS
Author/year Clinical trial Cancer Treatment N pts M F OS HR OS M HR OS M range OS F HR OS F 
range
Hodi et al. 
2010 [13] Phase III
Melanoma 
St. III, IV
Ipilimumab + Gp100 403 247 156 0.68 0.66 0.50-0.87 0.72 0.52-0.99
Ipilimumab 137 81 56 0.66 0.54 0.37-0.77 0.81 0.55-1.20
Gp100 136 73 63
Robert et al. 
2011 [16] Phase III
Melanoma 
St. IV
Ipilimumab + 
Dacarbazina 250 152 98 0.72 -0.35
* -0.60- -0.1* -0.15* -0.46- -0.16*
Dacarbazina 252 149 103
Motzer et al. 
2015 [29] Phase III
Kidney 
St. IV
Nivolumab 3 mg/kg 410 315 95 0.73(0.57-0.93) 0.73 0.58-0.92 0.84 0.57-1.24
Eveolimus 411 304 107
Bellmont et 
al. 2017 [30] Phase III
Urothelial 
St. IV
Pembrolizumab 200 
mg q21 270 200 70 0.73 (0.59-0.91) 0.73 0.56-0.94 0.78 0.49-1.24
Chemotherapy 272 202 70
Brahmer et 
al. 2015 [26] Phase III
NSCLC St. 
IIIB/IV
Nivolumab 3 mg/kg 135 11 24 0.59(0.44-0.79) 0.57 0.41-0.78 0.67 0.36-1.25
Docetaxel 137 97 40
Borghaei et 
al. 2015 [27] Phase III
NSCLC 
ADK St. 
IIIB/IV
Nivolumab 3 mg/kg 292 151 141 0.73 (0.59-0.89) 0.73 0.56-0.96 0.78 0.58-1.04
Docetaxel 290 168 122
Carbone et al. 
2017 [28] Phase III
NSCLC St. 
IV/recurent
Nivolumab 3 mg/kg 271 184 87 1.02 (0.80-1.30) 0.87 0.74-1-.26 1.15 0.79-1.66
Chemotherapy 270 148 122
Herbst et al. 
2016 [22] Phase II/III
NCSLC 
St. IV
Pembrolizumab 2 
mg/kg 345 212 133 0.71(0.58-0.88)
0.65 0.52-0.81 0.69 0.51-0.94
Pembrolizumab 10 
mg/kg 346 213 133 0.61 (0.49-0.75)
Docetaxel 343 209 134
Rittmeyer et 
al. 2017 [25] Phase III
NSCLC St. 
IIIB/IV
Atezolizumab 1200 mg 425 261 164 0.73 (0.62-0.87) 0.79 0.64-0.97 0.64 0.49-0.85
Docetaxel 425 259 166
*Value expressed as Log HR
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The aim of our study is to analyze differences in the 
response to ICIs treatment in both sexes.
Interestingly in our study we observed a better 
OS associated to the anti-CTLA4 treatment in males 
compared to females. As far as anti-PD-1 treatment is 
concerned, despite the sample size and the number of 
clinical trials evaluated considerably wider than those for 
the anti CTLA-4 analysis, statistical significance has not 
been achieved.
Moreover we observed lower HR in males compared 
to women both for OS and PFS for anti-PD-1 treatments. 
Instead for anti PD-L1 antibodies it was not possible to 
perform a meta-analysis since in literature only one study 
presented HR for females and males.
It has been demonstrated that females have an 
immune system that acts predominantly by T helper (CD4+) 
response, in particular with a humoral response in various 
species and in cell culture systems in presence of high levels 
of estrogen and progesterone. [4] Hormone receptors are 
present in many cells of immune system; especially the 
estrogen receptor is expressed in lymphocytes, macrophages 
and dendritic cells, while progesterone receptor is present, 
also in the natural killer cells. [4, 51, 52] Conversely, males’ 
immune system mainly acts through a cytotoxic action, 
having at baseline a higher number of T CD8 + lymphocytes 
and a lower CD4 + / CD8 + ratio than females. [4] This 
last observation could results in a stronger CD8+ response 
against tumor and in a better sensibility to ICIs.
Furthermore it is important to underline that many 
genes involved in the immune response are located on 
the X chromosome and therefore they showed a higher 
expression in females. These genes encode for receptors 
belonging to the class of PRRs, as TLR4 and TLR7, 
involved in a humoral response, some receptors for 
interleukins and some transcription factors such as FOXP3 
that acts as negative regulator. [5, 53].
Interestingly Griesbeck demonstrated, in a murine 
model, that the production of IFN-alfa after TRL7 
stimulations was higher in female dendritic cells than 
males, suggesting a crucial role of IRF5 gene. [54].
Figure 3: Forest Plot for OS with anti-PD-1.
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Table 2: Clinical trials selected for PFS
Author/year Clinical 
trial
Cancer Treatment N pts M F PFS HR PFS M 
HR
PFS M 
range
PFS F HR PFS F 
range
Ribas et al. 
2015 [32] Phase II Melanoma St. IV
Pembrolizumab 2 
mg/kg 180 104 76 0.57(0.45-0.73) 0.54 0.39-0.74 0.61 0.41-0.92
Pembrolizumab 10 
mg/kg 181 109 72 0.50(0.39-0.64) 0.50 0.36-0.68 0.52 0.34-0.78
Chemotherapy 179 114 65
Brahmer et al. 
2015 [26] Phase III
NSCLC St. IIIB/
IV
Nivolumab 3 mg/kg 135 11 24 0.59(0.44-0.79) 0.57 0.41-0.78 0.67 0.36-1.25
Docetaxel 137 97 40
Borghaei et al. 
2015 [27] Phase III
NSCLC ADK St. 
IIIB/IV
Nivolumab 3 mg/kg 292 151 141 0.92(0.77-1.1) 0.81 0.63-1.04 1.04 0.80-1.37
Docetaxel 290 168 122
Carbone et al. 
2017 [28] Phase III
NSCLC St. IV/
recurent
Nivolumab 3 mg/kg 271 184 87 1.15(0.91-1.45) 1.05 0.81-1.37 1.36 0.98-1.90
Chemotherapy 270 148 122
Herbst et al. 
2016 [22] Phase II/III NCSLC St. IV
Pembrolizumab 2 
mg/kg 345 212 133 0.88(0.74-1.05)
0.78 0.64-0.94 1.02 0.78-1.32
Pembrolizumab 10 
mg/kg 346 213 133 0.79(0.66-0.94)
Docetaxel 343 209 134
Reck et al. 
2016 [23] Phase III NSCLC St. IV
Pembrolizumab 
200 mg 154 92 62 0.50(0.37-0.68) 0.39 0.26-0.58 0.75 0.46-1.21
Chemotherapy 151 95 56
Figure 4: Forest Plot for PFS with anti-PD-1.
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Indeed, several genes, whose function is implicated 
in immune system activity, have in their promoter an 
estrogen response element (ERE), such the IRF5 gene, 
which encodes for the IFN regulatory factor 5. [54, 
55] IFNγ gene presents also an ERE on its promoter, 
with a transcription directly regulated by estrogens. [4] 
IFNγ consequently promotes, through a IRF1 mediated 
mechanism, the expression of CD-274 gene, coding for 
the PD-L1, and of IDO gene, encoding for indoleamine-
2,3-dioxygenase, an enzyme that transform tryptophan 
into kynurenine, leading to an immunosuppressive tumor 
microenvironment in which the T cells’ proliferation and 
activity are inhibited. [56-58].
Several studies demonstrated that Treg cells express 
high immune inhibitory receptors, such as CTLA-4 and PD-
1. Paradoxically, on Treg cells the binding of these receptors 
with the ligand leads to an increase in the activation of the 
Treg cells themselves, with consequent inhibitory activity 
on T lymphocytes. [59] As it has been observed in different 
preclinical and clinical studies, the use of anti-CTLA-4 
antibodies could induce the depletion of Treg cells. [60, 
61] As Treg cells are present at higher levels in males, 
this mechanism could affect the different response to anti-
CTLA-4 in the two sexes. [4] As far as PD-1, despite having 
a Treg cell activation function similar to that described for 
CTLA-4, an inhibitory action on Treg cells has not been 
reported in literature.
The inhibitory activity of anti CTLA-4 on Treg 
cells also occurs at the gastrointestinal tract, with 
dysregulation of their immunomodulatory function and 
consequent widespread inflammation, particularly at the 
colon level. [62, 63] This is certainly the basis of the 
gastrointestinal toxicity mechanism but also responsible 
for the modification of the intestinal flora. The function 
of microbiota is relevant for the modulation of the 
immune system; moreover it’s affected by gender and 
diet differences, and it is also involved in immune-related 
toxicity mechanisms during treatement. [64] The effect 
of the microbiota may also affect the different efficacy 
observed according to the sex, and among different drugs 
with different mechanism of action.
Furthermore the differences of PFS and OS HR 
between anti-CTLA-4 and anti-PD-1 could depend on their 
different action’s mechanism. Anti-CTLA-4 and anti PD-1 
act in different point of cancer- immune cycle (in priming 
phase and killing cancer cells phase respectively): while 
anti CTLA4 enhances early T cell activation, anti-PD-1 
reverse the exhausted state of existing effector T cells. 
Thus the different activation status of antigen-specific T 
cells in males and females could influences the response 
not only to monotherapy but mostly to combination of 
ICIs.
Moreover, we have to consider also the differences 
in gender and not only in sex. The environmental estrogens 
could have an impact on immune response such as 
xenoestrogens added in cosmetic or hormone replacement 
therapy and oral contraceptives.
Our work presents some weakness and limitations 
depending on the trials’ heterogeneity, on the different 
cancer type considered that could have different 
immunogenicity and on the absence of information about 
hormonal status and on PD-L1 status according to sex.
Furthermore, some studies enrolled patients 
according to biomarkers expression at different cut-off, for 
example PD-L1 for Pembrolizumab trials or for first-line 
Nivolumab, while for anti-CTLA-4 trials none biomarker 
was used as inclusion criteria. Considering the previously 
discussed sex related implications on PD-L1 expression, 
this heterogeneity between trials could be considered as a 
bias of our meta-analysis.
Moreover, this is not an individual patients’ data 
meta-analysis, leading to exclusion of many literature data. 
We also excluded trials with control arm treated with ICIs 
and trials studying combination immunotherapy, even if 
it could be interesting to analyze the impact of the double 
block of immune target in the two sexes. However, we 
decided to include only Phase II-III trials and to exclude 
trials with combination of ICIs to reduce the possible bias.
These observations need to be confirmed by further 
studies, in particular by direct comparison of males 
and females on a homogeneous and numerically larger 
sample, with an analysis of lymphocyte subpopulations, of 
expression of different markers on the surface of immune 
cells, of mutational burden, with the dosage of cytokines 
and antibodies during therapy, with an accurate study of 
the microbiota and studying the possible associations with 
immune related adverse events (irAE).
In conclusion, the differences in immune response 
between males and females could be relevant to determine 
the response and the resistance to ICIs and to identify new 
immunological targets in order to draw studies exploring 
novels combinations of immunotherapy agents.
MATERIALS AND METHODS
Data retrieval
We conducted a meta-analysis of Clinical Trials 
including treatment with immunotherapy (anti-CTLA-4, 
anti-PD1, anti-PD-L1), which data were published up to 
June 2017. The databases of PubMed, www.clinicaltrials.
gov and the American Society of Clinical Oncology (ASCO) 
University Meeting was searched for relevant publications 
about lung (NSCLC), renal cells (RCC), head and neck, 
urothelial cancers and melanoma. Furthermore, we completed 
the data retrieval with a manual search between the references 
of the previously selected articles. The selection of items was 
restricted to phase II and phase III trials.
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Data extraction
Three independent reviewers selected and analyzed 
all the articles. The following data were extracted: type of 
study; type of cancer; stage of disease; arms of treatment; 
number and sex of patients for each arm of treatment; 
PFS and OS expressed as HR for the whole population 
and differentiated by sex. The abstracts were excluded for 
lack of subgroups’ analysis. Similarly, the articles where 
subgroup analysis differentiated by was not reported were 
excluded from the final statistical analysis. The studies in 
which the control arm received ICIs where excluded too.
Statistical analysis
Hazard Ratios (HR) with 95% confidence intervals 
(CIs) for PFS and OS were extracted from papers. 
Subgroups random-effects meta-analysis (inverse-variance 
weighted method) were performed to evaluate differences 
in treatment effects according to patients’ sex. In all 
figures the derived results are reported as conventional 
meta-analysis forest plots, with a HR<1.0 indicating better 
outcome in the experimental arm. All the analysis were 
accomplished using Stata/SE14.0 (Stata Corp, College 
Station, TX, USA).
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